Cargando…

Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China

China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Fuqiang, Shen, Lipin, Li, Li, Wang, Huaqing, Wang, Fuzhen, Bi, Shengli, Liu, Jianhua, Zhang, Guomin, Wang, Feng, Zheng, Hui, Sun, Xiaojin, Miao, Ning, Yin, Zundong, Feng, Zijian, Liang, Xiaofeng, Wang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403029/
https://www.ncbi.nlm.nih.gov/pubmed/28418296
http://dx.doi.org/10.3201/eid2305.161477
_version_ 1783231352627265536
author Cui, Fuqiang
Shen, Lipin
Li, Li
Wang, Huaqing
Wang, Fuzhen
Bi, Shengli
Liu, Jianhua
Zhang, Guomin
Wang, Feng
Zheng, Hui
Sun, Xiaojin
Miao, Ning
Yin, Zundong
Feng, Zijian
Liang, Xiaofeng
Wang, Yu
author_facet Cui, Fuqiang
Shen, Lipin
Li, Li
Wang, Huaqing
Wang, Fuzhen
Bi, Shengli
Liu, Jianhua
Zhang, Guomin
Wang, Feng
Zheng, Hui
Sun, Xiaojin
Miao, Ning
Yin, Zundong
Feng, Zijian
Liang, Xiaofeng
Wang, Yu
author_sort Cui, Fuqiang
collection PubMed
description China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1–29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre–recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China’s HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies.
format Online
Article
Text
id pubmed-5403029
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-54030292017-05-12 Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China Cui, Fuqiang Shen, Lipin Li, Li Wang, Huaqing Wang, Fuzhen Bi, Shengli Liu, Jianhua Zhang, Guomin Wang, Feng Zheng, Hui Sun, Xiaojin Miao, Ning Yin, Zundong Feng, Zijian Liang, Xiaofeng Wang, Yu Emerg Infect Dis Research China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1–29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre–recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China’s HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies. Centers for Disease Control and Prevention 2017-05 /pmc/articles/PMC5403029/ /pubmed/28418296 http://dx.doi.org/10.3201/eid2305.161477 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Cui, Fuqiang
Shen, Lipin
Li, Li
Wang, Huaqing
Wang, Fuzhen
Bi, Shengli
Liu, Jianhua
Zhang, Guomin
Wang, Feng
Zheng, Hui
Sun, Xiaojin
Miao, Ning
Yin, Zundong
Feng, Zijian
Liang, Xiaofeng
Wang, Yu
Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
title Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
title_full Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
title_fullStr Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
title_full_unstemmed Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
title_short Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
title_sort prevention of chronic hepatitis b after 3 decades of escalating vaccination policy, china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403029/
https://www.ncbi.nlm.nih.gov/pubmed/28418296
http://dx.doi.org/10.3201/eid2305.161477
work_keys_str_mv AT cuifuqiang preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT shenlipin preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT lili preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT wanghuaqing preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT wangfuzhen preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT bishengli preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT liujianhua preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT zhangguomin preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT wangfeng preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT zhenghui preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT sunxiaojin preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT miaoning preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT yinzundong preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT fengzijian preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT liangxiaofeng preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina
AT wangyu preventionofchronichepatitisbafter3decadesofescalatingvaccinationpolicychina